Get the Stockscreener App
204.80
2.16%
4.33
After Hours:
204.80
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $204.80, with a volume of 1.24M.
It is up +2.16% in the last 24 hours and up +7.06% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$200.47
Open:
$202.81
24h Volume:
1.24M
Relative Volume:
0.32
Market Cap:
$317.61B
Revenue:
$58.80B
Net Income/Loss:
$10.24B
P/E Ratio:
62.46
EPS:
3.2788
Net Cash Flow:
$8.98B
1W Performance:
+0.38%
1M Performance:
+7.06%
6M Performance:
+141.82%
1Y Performance:
+203.00%
1-Day Range:
$202.55
$205.30
1-Week Range:
$199.50
$205.30
52-Week Range:
$66.16
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
204.80 | 310.90B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
927.03 | 807.59B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.18 | 564.92B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
208.38 | 369.65B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.07 | 285.17B | 64.93B | 18.26B | 12.36B | 7.2751 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca stock holds steady after Assetmark Inc. and Pursuit Wealth buy shares - Traders Union
AstraZeneca (AZN) Sees Leadership Changes in CDC Announced by Pr - GuruFocus
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
AstraZeneca (AZN) Advances Portfolio with Strategic Update - GuruFocus
AstraZeneca (AZN) Faces Rising Drug Prices Amid Senate Scrutiny - GuruFocus
Pursuit Wealth Management LLC Takes Position in Astrazeneca Plc $AZN - MarketBeat
Assetmark Inc. Buys 25,004 Shares of Astrazeneca Plc $AZN - MarketBeat
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance Australia
AstraZeneca stock holds steady after $191 million grant for Albemarle facility approved - Traders Union
ZWJ Investment Counsel Inc. Lowers Holdings in Astrazeneca Plc $AZN - MarketBeat
Bingham Private Wealth LLC Takes $669,000 Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to unlock new upside? - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): Why does its oncology dominance matter more now for U.S. inves - AD HOC NEWS
AstraZeneca Targets Early Detection in China With New ATTR Heart Disease Study - TipRanks
AstraZeneca plc stock (GB0009895292): Is oncology dominance strong enough to unlock new upside? - AD HOC NEWS
32,091 Shares in Astrazeneca Plc $AZN Bought by Third View Private Wealth LLC - MarketBeat
AstraZeneca Adds to Demands on Hospitals Seeking Drug Discounts - Bloomberg Law News
Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - Yahoo Finance
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to drive sustained U.S. in - AD HOC NEWS
AstraZeneca India to divest Bengaluru manufacturing site for INR 3,400 crore - Prop News Time
Astrazeneca Plc $AZN Shares Bought by Apollon Wealth Management LLC - MarketBeat
Parnassus Value Equity Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage - Yahoo Finance
Is AstraZeneca Still in Focus After Strong Market Momentum? - Kalkine Media
AstraZeneca Wins Strong Shareholder Backing at 2026 AGM - The Globe and Mail
AstraZeneca faces China headwinds and key drug launches as two banks back 20% upside - Yahoo Finance UK
AstraZeneca India Expands Cancer Drug Use, Stock Gains on Approval - Whalesbook
ASTRAZENECA : UBS gives a Buy rating - marketscreener.com
ASTRAZENECA : Jefferies reaffirms its Buy rating - marketscreener.com
PDL1 Antibody Reagent Market is Going to Boom: AstraZeneca • Pfizer • Novartis • Abcam - openPR.com
AstraZeneca shareholders approve all resolutions at annual general meeting - Investing.com
AstraZeneca shareholders approve all resolutions at annual general meeting By Investing.com - Investing.com UK
AstraZeneca (AZN) shareholders back all AGM resolutions and buyback - Stock Titan
AstraZeneca Triumphs at AGM: All Resolutions Passed - Devdiscourse
AstraZeneca announces all AGM resolutions including Special Resolutions 10-13 passed - marketscreener.com
AstraZeneca, Sun Dismiss Patent Suits Over Three Diabetes Drugs - Bloomberg Law News
Ideaya Biosciences announces clinical collaboration with AstraZeneca for lung cancer study - Investing.com India
Erste Group Bank Comments on Astrazeneca FY2026 Earnings - MarketBeat
$1.05 Bn Biopharmaceutical CXO MarketsGlobal Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics - Yahoo Finance
IDEAYA Biosciences (NASDAQ: IDYA) teams with AstraZeneca on IDE849-Imfinzi SCLC trial - Stock Titan
Cowen Maintains Buy on AstraZeneca PLC (AZN) March 2026 - Meyka
AstraZeneca Wants 25 Opt-Ins Axed From Pay Bias Suit - Law360
AstraZeneca (NYSE: AZN) delists 0.700% Notes due 2026 from NYSE - Stock Titan
AstraZeneca Extends Fasenra’s Runway With New Long-Term Safety Study - TipRanks
AstraZeneca : Sustainability Data Reporting Criteria 2025 - marketscreener.com
AstraZeneca : Assurance Report for Sustainability Data Annex 2025 - marketscreener.com
AstraZeneca : Sustainability Data Annex 2025 - marketscreener.com
The Zacks Analyst Blog Highlights AstraZeneca, HSBC, Walt Disney, Oak Valley Bancorp and BV Financial - Yahoo Finance
AstraZeneca Partners with Telangana Government to Introduce AI-Based Lung Cancer Screening - The Indian Practitioner
Sivik Global Healthcare LLC Makes New Investment in Astrazeneca Plc $AZN - MarketBeat
Naviter Wealth LLC Sells 12,014 Shares of Astrazeneca Plc $AZN - MarketBeat
£20,000 invested in AstraZeneca shares 5 years ago is now worth… - Fool UK
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.13%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):